SuperworthEmergent BioSolutions EPS EBS
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$3.55
- Latest quarter, Q2 FY26
- −$3.49
- Fiscal year 2025
- $0.84
Emergent BioSolutions' earnings per share was −$3.55 over the twelve months to Jun 30, 2026, down 245% on a year earlier.
In its latest quarter, Q2 FY26, it was −$3.49.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.84 | n/a |
| FY2024 | −$3.73 | n/a |
| FY2023 | −$14.90 | n/a |
| FY2022 | −$4.24 | −204% |
| FY2021 | $4.08 | −28% |
| FY2020 | $5.66 | +444% |
| FY2019 | $1.04 | −15% |
| FY2018 | $1.22 | −28% |
| FY2017 | $1.69 | +61% |
| FY2016 | $1.05 | −16% |
| FY2015 | $1.25 | +71% |
| FY2014 | $0.73 | −13% |
| FY2013 | $0.84 | +31% |
| FY2012 | $0.64 | +7% |
| FY2011 | $0.60 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$3.49 | n/a | −$3.55 | |
| Q1 FY26 | $0.07 | −94% | −$0.28 | |
| Q4 FY25 | −$1.04 | n/a | $0.84 | |
| Q3 FY25 | $0.91 | −56% | $1.30 | |
| Q2 FY25 | −$0.22 | n/a | $2.45 | |
| Q1 FY25 | $1.19 | +600% | −$2.71 | |
| Q4 FY24 | −$0.58 | n/a | −$3.73 | |
| Q3 FY24 | $2.06 | n/a | −$4.10 | |
| Q2 FY24 | −$5.38 | n/a | −$11.24 | |
| Q1 FY24 | $0.17 | n/a | −$11.02 | |
| Q4 FY23 | −$0.95 | n/a | −$14.90 | |
| Q3 FY23 | −$5.08 | n/a | −$15.29 |
Against its peers
Companies in Drug Manufacturers - General nearest Emergent BioSolutions' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| EBSEmergent BioSolutions | −$3.55 | −245% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Emergent BioSolutions
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.